Limits...
Roles of DPY30 in the Proliferation and Motility of Gastric Cancer Cells.

Lee YJ, Han ME, Baek SJ, Kim SY, Oh SO - PLoS ONE (2015)

Bottom Line: Various types of histone methylation have been associated with cancer progression.Depending on the methylation site in histone proteins, its effects on transcription are different.Its knockdown by siRNA decreased the proliferation, migration, and invasion of gastric cancer cells, whereas its overexpression showed the opposite effects.

View Article: PubMed Central - PubMed

Affiliation: Departments of Anatomy, School of Medicine, Pusan National University, Busan, Republic of Korea.

ABSTRACT
Various types of histone methylation have been associated with cancer progression. Depending on the methylation site in histone proteins, its effects on transcription are different. DPY30 is a common member of SET1/MLL histone H3K4 methyltransferase complexes. However, its expression and roles in gastric cancer have been poorly characterized. To determine whether DPY30 has pathophysiological roles in gastric cancer, its expression and roles were examined. Immunohistochemistry and real time PCR showed up-regulation of DPY30 expression in some gastric cancer cell lines and patients' tissues. Its knockdown by siRNA decreased the proliferation, migration, and invasion of gastric cancer cells, whereas its overexpression showed the opposite effects. These results indicate that DPY30 has critical roles in the proliferation, migration, and invasion of gastric cancer cells, and suggest DPY30 might be a therapeutic target in gastric cancer.

No MeSH data available.


Related in: MedlinePlus

Overexpression of DPY30 in gastric cancers.(A-D) Immunohistochemical staining demonstrated the overexpression of DPY30 in gastric cancer tissues. Notably its overexpression was obviously greater in invading cancer cells (B-D) than in normal gastric mucosa (A). (E) The mRNA level of DPY30 in gastric cancer cells (SNU1, SNU16, SNU216, SNU620, SNU638 and NCI-N87) and normal gastric epithelial cell (HFE145) was determined by real-time PCR using specific primers for DPY30. GAPDH was used to normalize data. Values shown are the means ± SDs of the three independent experiments performed in triplicate. *, p < 0.01 (Student’s t test, versus HFE145). (F) The expression of DPY30 in gastric cancer tissues was examined by real-time PCR using specific primers for DPY30. GAPDH was used to normalize data. Values are the means ± SDs of three independent experiments performed in triplicate. *, p < 0.01; **, p < 0.05 (Student’s t test, versus normal).
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4493084&req=5

pone.0131863.g001: Overexpression of DPY30 in gastric cancers.(A-D) Immunohistochemical staining demonstrated the overexpression of DPY30 in gastric cancer tissues. Notably its overexpression was obviously greater in invading cancer cells (B-D) than in normal gastric mucosa (A). (E) The mRNA level of DPY30 in gastric cancer cells (SNU1, SNU16, SNU216, SNU620, SNU638 and NCI-N87) and normal gastric epithelial cell (HFE145) was determined by real-time PCR using specific primers for DPY30. GAPDH was used to normalize data. Values shown are the means ± SDs of the three independent experiments performed in triplicate. *, p < 0.01 (Student’s t test, versus HFE145). (F) The expression of DPY30 in gastric cancer tissues was examined by real-time PCR using specific primers for DPY30. GAPDH was used to normalize data. Values are the means ± SDs of three independent experiments performed in triplicate. *, p < 0.01; **, p < 0.05 (Student’s t test, versus normal).

Mentions: To investigate DPY30 expression in human gastric cancer, we performed immunohistochemistry using a gastric cancer tissue array or archival paraffin-embedded tissue sections. In normal gastric tissues, DPY30 expression was difficult to detect (Fig 1A), but in cancer tissues DPY30 protein was widely overexpressed (Fig 1B–1D). Notably, DPY30 was overexpressed in invading gastric cancer cells (Fig 1B–1D). Furthermore, we determined mRNA levels of DPY30 in one immortalized normal gastric epithelial cell line (HFE145) and six gastric cancer-derived cell lines (SNU1, SNU16, SNU216, SNU620, SNU638 and NCI-N87) using real-time PCR. The mRNA level of DPY30 was considerably higher (fold change > 5) in SNU1 and SNU16 than in HFE145 cells, whereas the expression level of DPY30 in SNU216, SNU620 and SNU638 was similar to those in HFE145 cells and was lower (fold change > 10) in NCI-N87 (Fig 1E). We also checked mRNA levels of DPY30 in gastric cancer tissues. DPY30 was highly expressed in 15 cases (15/23, 65%) as compared with normal tissues (Fig 1F). These results indicate that DPY30 is highly expressed in some human gastric cancers.


Roles of DPY30 in the Proliferation and Motility of Gastric Cancer Cells.

Lee YJ, Han ME, Baek SJ, Kim SY, Oh SO - PLoS ONE (2015)

Overexpression of DPY30 in gastric cancers.(A-D) Immunohistochemical staining demonstrated the overexpression of DPY30 in gastric cancer tissues. Notably its overexpression was obviously greater in invading cancer cells (B-D) than in normal gastric mucosa (A). (E) The mRNA level of DPY30 in gastric cancer cells (SNU1, SNU16, SNU216, SNU620, SNU638 and NCI-N87) and normal gastric epithelial cell (HFE145) was determined by real-time PCR using specific primers for DPY30. GAPDH was used to normalize data. Values shown are the means ± SDs of the three independent experiments performed in triplicate. *, p < 0.01 (Student’s t test, versus HFE145). (F) The expression of DPY30 in gastric cancer tissues was examined by real-time PCR using specific primers for DPY30. GAPDH was used to normalize data. Values are the means ± SDs of three independent experiments performed in triplicate. *, p < 0.01; **, p < 0.05 (Student’s t test, versus normal).
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4493084&req=5

pone.0131863.g001: Overexpression of DPY30 in gastric cancers.(A-D) Immunohistochemical staining demonstrated the overexpression of DPY30 in gastric cancer tissues. Notably its overexpression was obviously greater in invading cancer cells (B-D) than in normal gastric mucosa (A). (E) The mRNA level of DPY30 in gastric cancer cells (SNU1, SNU16, SNU216, SNU620, SNU638 and NCI-N87) and normal gastric epithelial cell (HFE145) was determined by real-time PCR using specific primers for DPY30. GAPDH was used to normalize data. Values shown are the means ± SDs of the three independent experiments performed in triplicate. *, p < 0.01 (Student’s t test, versus HFE145). (F) The expression of DPY30 in gastric cancer tissues was examined by real-time PCR using specific primers for DPY30. GAPDH was used to normalize data. Values are the means ± SDs of three independent experiments performed in triplicate. *, p < 0.01; **, p < 0.05 (Student’s t test, versus normal).
Mentions: To investigate DPY30 expression in human gastric cancer, we performed immunohistochemistry using a gastric cancer tissue array or archival paraffin-embedded tissue sections. In normal gastric tissues, DPY30 expression was difficult to detect (Fig 1A), but in cancer tissues DPY30 protein was widely overexpressed (Fig 1B–1D). Notably, DPY30 was overexpressed in invading gastric cancer cells (Fig 1B–1D). Furthermore, we determined mRNA levels of DPY30 in one immortalized normal gastric epithelial cell line (HFE145) and six gastric cancer-derived cell lines (SNU1, SNU16, SNU216, SNU620, SNU638 and NCI-N87) using real-time PCR. The mRNA level of DPY30 was considerably higher (fold change > 5) in SNU1 and SNU16 than in HFE145 cells, whereas the expression level of DPY30 in SNU216, SNU620 and SNU638 was similar to those in HFE145 cells and was lower (fold change > 10) in NCI-N87 (Fig 1E). We also checked mRNA levels of DPY30 in gastric cancer tissues. DPY30 was highly expressed in 15 cases (15/23, 65%) as compared with normal tissues (Fig 1F). These results indicate that DPY30 is highly expressed in some human gastric cancers.

Bottom Line: Various types of histone methylation have been associated with cancer progression.Depending on the methylation site in histone proteins, its effects on transcription are different.Its knockdown by siRNA decreased the proliferation, migration, and invasion of gastric cancer cells, whereas its overexpression showed the opposite effects.

View Article: PubMed Central - PubMed

Affiliation: Departments of Anatomy, School of Medicine, Pusan National University, Busan, Republic of Korea.

ABSTRACT
Various types of histone methylation have been associated with cancer progression. Depending on the methylation site in histone proteins, its effects on transcription are different. DPY30 is a common member of SET1/MLL histone H3K4 methyltransferase complexes. However, its expression and roles in gastric cancer have been poorly characterized. To determine whether DPY30 has pathophysiological roles in gastric cancer, its expression and roles were examined. Immunohistochemistry and real time PCR showed up-regulation of DPY30 expression in some gastric cancer cell lines and patients' tissues. Its knockdown by siRNA decreased the proliferation, migration, and invasion of gastric cancer cells, whereas its overexpression showed the opposite effects. These results indicate that DPY30 has critical roles in the proliferation, migration, and invasion of gastric cancer cells, and suggest DPY30 might be a therapeutic target in gastric cancer.

No MeSH data available.


Related in: MedlinePlus